AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI-001 for the Treatment of Hemophagocytic Lymphohistiocytosis SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...